NCT05834764 - Pyrotinib in Women With High-risk in Early Stage Breast Cancer | Biotech Hunter

Enrollment

188

Participants

Timeline

Start Date

April 8, 2023

Primary Completion Date

June 1, 2026

Study Completion Date

December 31, 2028

Conditions

HER2-positive Breast Cancer

Interventions

DRUG

Pyrotinib

Pyrotinib after anti-HER2 therapy（Trastuzumab combined with Pertuzumab or T-DM1）

Trial Locations (1)

RECRUITING

JiangSu Province Hospital/ The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors

collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER